Page last updated: 2024-09-04

olmesartan and Carcinoma, Ehrlich Tumor

olmesartan has been researched along with Carcinoma, Ehrlich Tumor in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abd-Alhaseeb, MM; Abou-El-Ela, SH; Moustafa, YM; Zaitone, SA	1

Other Studies

1 other study(ies) available for olmesartan and Carcinoma, Ehrlich Tumor

Article	Year
Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7). PloS one, 2014, Volume: 9, Issue:1 Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Female; Imidazoles; Immunohistochemistry; Insulin-Like Growth Factor I; Mice; Neovascularization, Pathologic; Niacinamide; Peptide Fragments; Phenylurea Compounds; Receptor, IGF Type 1; Sorafenib; Tetrazoles; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2014

Article

Year

Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7).

PloS one, 2014, Volume: 9, Issue:1

Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Female; Imidazoles; Immunohistochemistry; Insulin-Like Growth Factor I; Mice; Neovascularization, Pathologic; Niacinamide; Peptide Fragments; Phenylurea Compounds; Receptor, IGF Type 1; Sorafenib; Tetrazoles; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2014